Invivyd Announces That The New England Journal Of Medicine Has Published A Peer-reviewed Letter To The Editor Describing The Pemgarda (Pemivibart) Immunobridging Emergency Use Authorization Pathway, As Well As An Updated Correlate Of Protection Curve...

Invivyd 宣布《新英格兰医学杂志》已发表了一封经过同行评审的编辑信，描述了 Pemgarda（Pemivibart）免疫桥接紧急使用授权途径，以及更新的保护相关曲线......

Benzinga · 11/14 20:07

Invivyd Announces That The New England Journal Of Medicine Has Published A Peer-reviewed Letter To The Editor Describing The Pemgarda (Pemivibart) Immunobridging Emergency Use Authorization Pathway, As Well As An Updated Correlate Of Protection Curve For Prevention Of Symptomatic Covid-19 Via Recombinant Monoclonal Antibodies Such As Pemivibart

Invivyd 宣布《新英格兰医学杂志》已发表了一封经过同行评审的编辑信，描述了 Pemgarda（Pemivibart）免疫桥接紧急使用授权途径，以及更新的保护相关曲线，旨在通过重组单克隆抗体如 Pemivibart 预防有症状的 Covid-19

译文内容由第三方软件翻译。

以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。